文献速递神经眼科

经颅直流电刺激治疗Charles Bonnet综合征视觉幻觉:一项随机安慰剂对照交叉试验

Transcranial Direct Current Stimulation in the Treatment of Visual Hallucinations in Charles Bonnet Syndrome: A Randomized Placebo-Controlled Crossover Trial.
PubMed 文献 · Ophthalmology · 2022-07-09

这项随机双掩蔽安慰剂对照交叉试验纳入16例继发于眼病的Charles Bonnet综合征患者,比较连续4天主动与安慰剂阴极经颅直流电刺激视觉皮层(Oz,电流密度0.29 mA/cm²)对视觉幻觉的影响。主动刺激较安慰剂显著降低视觉幻觉频率,效应量中到大;刺激耐受良好,无显著不良事件。

要点

  • 主动抑制性tDCS较安慰剂显著降低CBS患者视觉幻觉频率,效应量中到大。
  • 治疗前枕叶兴奋性较高的患者更可能报告阳性治疗反应。
  • 刺激在所有参与者中耐受良好,无显著不良事件,包括原有视觉损害无恶化。

核心结论

  • 抑制性tDCS作用于视觉皮层可能降低CBS患者的视觉幻觉频率,尤其在刺激前枕叶兴奋性较高者中。
  • tDCS可能为CBS提供一种无显著副作用的可行干预选择,需更大规模临床试验进一步明确其疗效。

研究设计与样本

  • 随机、双掩蔽、安慰剂对照交叉试验,纳入16例继发于眼病所致视觉损害的CBS患者。
  • 所有参与者接受连续4天主动与安慰剂阴极刺激视觉皮层(Oz,电流密度0.29 mA/cm²),分2个治疗周,间隔4周洗脱期。

主要发现

  • 与安慰剂相比,主动抑制性刺激视觉皮层使东北视觉幻觉访谈测量的视觉幻觉频率显著降低,效应量中到大。
  • 视觉幻觉影响评分在安慰剂和主动条件下均改善,提示对CBS的支持与教育可能具有治疗获益。
  • 治疗开始时脑电图评估显示枕叶兴奋性较高的参与者更可能报告阳性治疗反应。
  • 刺激在所有参与者中耐受良好,无显著不良事件报告,包括原有视觉损害无恶化。

局限性

  • 原文在结论中提出需更大规模临床试验进一步明确tDCS对CBS的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the potential therapeutic benefits and tolerability of inhibitory transcranial direct current stimulation (tDCS) on the remediation of visual hallucinations in Charles Bonnet syndrome (CBS). DESIGN: Randomized, double-masked, placebo-controlled crossover trial. PARTICIPANTS: Sixteen individuals diagnosed with CBS secondary to visual impairment caused by eye disease experiencing recurrent visual hallucinations. INTERVENTION: All participants received 4 consecutive days of active and placebo cathodal stimulation (current density: 0.29 mA/cm2) to the visual cortex (Oz) over 2 defined treatment weeks, separated by a 4-week washout period. MAIN OUTCOME MEASURES: Ratings of visual hallucination frequency and duration following active and placebo stimulation, accounting for treatment order, using a 2 × 2 repeated-measures model. Secondary outcomes included impact ratings of visual hallucinations and electrophysiological measures. RESULTS: When compared with placebo treatment, active inhibitory stimulation of visual cortex resulted in a significant reduction in the frequency of visual hallucinations measured by the North East Visual Hallucinations Interview, with a moderate-to-large effect size. Impact measures of visual hallucinations improved in both placebo and active conditions, suggesting support and education for CBS may have therapeutic benefits. Participants who demonstrated greater occipital excitability on electroencephalography assessment at the start of treatment were more likely to report a positive treatment response. Stimulation was found to be tolerable in all participants, with no significant adverse effects reported, including no deterioration in preexisting visual impairment. CONCLUSIONS: Findings indicate that inhibitory tDCS of visual cortex may reduce the frequency of visual hallucinations in people with CBS, particularly individuals who demonstrate greater occipital excitability prior to stimulation. tDCS may offer a feasible intervention option for CBS with no significant side effects, warranting larger-scale clinical trials to further characterize its efficacy.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. daSilva Morgan K, Schumacher J, Collerton D, et al. Transcranial Direct Current Stimulation in the Treatment of Visual Hallucinations in Charles Bonnet Syndrome: A Randomized Placebo-Controlled Crossover Trial. Ophthalmology. 2022. PMID: 35817197. doi:10.1016/j.ophtha.2022.06.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。